Replies to post #80719 on Biotech Values

[ghmm]

RE: VRTX Seeks to Monetize Telaprevir EU Milestones from JNJ

Any guess on the risk adjusted discount (aside from the NPV discount)?

I guess they couldn't partner/sell one of their other compounds for a quality amount like they had been indicating on their calls. I wonder why they even PR'd this I would think it only material if they sell it.